Long-Term Risks Of Seroquel XR Will Be Focus Of Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca commits to a post-market study but says broadened indications for generalized anxiety disorder and major depressive disorder would not broaden the risks.